Literature DB >> 18539243

Treatment of sarcoidosis.

Robert P Baughman1, Ulrich Costabel, Ronald M du Bois.   

Abstract

Not all patients who have sarcoidosis require treatment. For those who require treatment, the outcome of sarcoidosis can be considered conceptually in three broad, and at least partially overlapping, groupings: acute, chronic, and refractory. Although corticosteroids remain the initial drug for most patients who require therapy, several steroid-sparing alternatives have been found effective in treating many aspects of sarcoidosis. Methotrexate is most commonly used cytotoxic agent used for chronic disease, but azathioprine and leflunomide also have been shown to be useful. The tumor necrosis factor antibody infliximab has proved useful in treating refractory sarcoidosis. These various agents led to a treatment strategy for the various aspects of sarcoidosis.

Entities:  

Mesh:

Year:  2008        PMID: 18539243     DOI: 10.1016/j.ccm.2008.03.012

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  22 in total

Review 1.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

2.  Antifibrotic role of HGF in sarcoidosis.

Authors:  Martin Faehling; Martin Hetzel; Diana Anders; Gerlinde Trischler; Max Bachem
Journal:  Lung       Date:  2012-02-05       Impact factor: 2.584

Review 3.  [Sarcoidosis].

Authors:  A Prasse; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2009-05       Impact factor: 0.743

Review 4.  Cardiac sarcoidosis.

Authors:  Matthew M Zipse; William H Sauer
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

5.  Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.

Authors:  Tobias Lahmer; Andreas Knopf; Ines Lanzl; Uwe Heemann; Klaus Thuermel
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 6.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

7.  Sarcoidosis Masquerading as Atrial Fibrillation: Interesting Case Discussion as Well as Recent Advances in Diagnosis and Management of Cardiac Sarcoidosis.

Authors:  Jefferson Curimbaba; João Pimenta; José Marcos Moreira; UlSilvia Carla Sousa Rodrigues; Ester Nei Aparecida Coletta; Carlos A C Pereira
Journal:  J Atr Fibrillation       Date:  2012-12-16

Review 8.  Sarcoidosis: a rheumatologist's perspective.

Authors:  Senol Kobak
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-10       Impact factor: 5.346

9.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

10.  Update on bioagent therapy in sarcoidosis.

Authors:  Vincent Cottin
Journal:  F1000 Med Rep       Date:  2010-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.